This patent covers a method of administering a hematopoeitic stem cell activatory factor into a host using a depot-like formulation. One of the problems of protien administration into humans is that many proteins have a short half live and therefore the pharmacokinetic profiles may not be adequate for stimulation of the biological response needed. This patent seems to overcome this...
IL-3 is a potent expander of hematopoietic stem cells. Unfortunately administration of proteins is associated with poor pharmacokinetics and the need to develop special formulations that can systemically deliver the protein. This patent covers peptide derivatives of IL-3 which have improved activity and pharmacological activity compared to administration of the whole protein. This patent...
This patent covers the composition of matter for several peptides as well as their utility for "stimulating the survival of, or neurite outgrowth in, cultured mammalian neuron, oligodendrocyte or fibroblast cells." The peptides are derived from the fibronectin domain of NCAM and have the ability to bind and activate the FGF2 receptor...
This patent is useful for the manipulation of stem cell expansion through interfering with Neuregulin-4 signaling by antibody. Specifically, the patent has 2 independent claims that cover an antibody capable of binding to sequences which appear to be those of Neuregulin-4 or its active portions.
This patent has one issued claim covering treatment of bone marrow cells with a compound (N-[4-[4-fluorophenyl)sulfonyl]phenyl]acetamide) and subsequent administration of the treated cells as a remedy for spinal cord injury.
This is a composition of matter patent on polypeptides homologous to insulin like growth factor binding protein (IGFBP). Various members of the IGFBP family, such as IGFBP-3, stimulate hematopoietic cell proliferation (Liu et al. Functional cloning of IGFBP-3 from human microvascular endothelial cells reveals its...
This patent is important for entities seeking to use the hematopoietic stem cell stimulatory/differentiation factor, granulocyte colony stimulating factor (G-CSF) that is produced in E. coli. The patent has 2 independent claims, the first to a vector encoding human G-CSF, and the second to a method of producing human G-CSF.
This is a composition of matter patent on compounds that modulate hedgehog signalling. Since hedgehog is important not only in stem cell proliferation, but also in cancer, this patent has uses both in regeneration and cancer control.
This patent is an example of how a good patent strategy is executed. WARF has filed originally patents on the actual embryonic stem cells and their composition of matter. One of the best ways of differentiating cells from embryonic stem cells involves growing the embryonic stem cells as embryoid bodies, then subsequently digesting the embryoid body and collecting the...
This patent teaches how to generate islet-like cells from fetal progenitors by culturing in the presence of one of the bone morphogenic proteins together with laminin or a laminin-like extracellular matrix. The patent has 3 independent claims all covering essentially the same process. The first one covers induction of growth and proliferation of "mammalian pancreatic epithelial cells into...